References




  1. Allen RP, Walters AS, Montplaisir J, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med. 2005;165(11):1286-1292.
  2. Baker CA, Hurley RA, Taber K. Update on obstructive sleep apnea: implications for neuropsychiatry. J Neuropsychiatry Clin Neurosci. 2016;28(3):A6-159.
  3. Burke RA, Faulkner MA. Gabapentin enacarbil for the treatment of restless legs syndrome (RLS). Expert Opin Pharmacother. 2011;12(18):2905-2014.
  4. Cheatle MD. Balancing the risks and benefits of opioid therapy for patients with chronic nonmalignant pain: have we gone too far or not far enough? Pain Med. 2018;19(4):642-645.
  5. Comella CL. Treatment of restless legs syndrome. Neurotherapeutics. 2014;11:177-187.
  6. Cundy KC, Sastry S, Luo W, et al. Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin. J Clin Pharmacol. 2008;48(12):1378-1388.
  7. Dineen KK, DuBois JM. Between a rock and a hard place: can physicians prescribe opioids to treat pain adequately while avoiding legal sanction? Am J Law Med. 2016;42:7-52.
  8. Giannaki CD, Hadjigeorgiou GM, Karatzaferi C, et al. Epidemiology, impact, and treatment options of restless legs syndrome in end-stage renal disease patients: an evidence-based review. Kidney Int. 2014;85(6):1275-1282.
  9. Guo S, Huang J, Jiang H, et al. Restless legs syndrome : from pathophysiology to clinical diagnosis and management. Front Aging Neurosci. 2017; 9:171.
  10. Health Professionals for Patients in Pain (HP3). Health professionals call on the CDC to address misapplication of its guideline on opioids for chronic pain through public clarification and impact evaluation. March 6, 2019. Available at: https://healthprofessionalsforpatientsinpain.org/the-letter-1.
  11. Hitt E. Medscape. Available at: https://www.medscape.com/viewarticle/761426.
  12. International Restless Legs Syndrome Study Group. Revised IRLSSG Diagnostic Criteria for RLS. 2012. Available at: http://irlssg.org/diagnostic-criteria/[Last accessed February 2023].
  13. Jiménez-Jiménez FJ, Alonso-Navarro H, García-Martín E, Agúndez JAG. Association between restless legs syndrome and peripheral neuropathy: A systematic review and meta-analysis. Eur J Neurol. 2021;28(7):2423-2442.
  14. Koo BB, Bagai K, Walters AS. Restless legs syndrome: current concepts about disease pathophysiology. Tremor Other Hyperkinet Mov (N Y). 2016;6:401.
  15. Mackie SE, McHugh RK, McDermott K, et al. Prevalence of restless legs syndrome during detoxification from alcohol and opioids. J Subst Abuse Treat. 2017;73:35-39.
  16. Mackie S, Winkelman JW. Long-term treatment of restless legs syndrome (RLS): an approach to management of worsening symptoms, loss of efficacy, and augmentation. CNS Drugs. 2015;29(5):351-357.
  17. Morin CM, Jarrin DC. Epidemiology of insomnia: prevalence, course, risk factors, and public health burden. Sleep Med Clin. 2022;17(2):173-191.
  18. Rubin R. Limits on opioid prescribing leave patients with chronic pain vulnerable. 2019;32(21):2059-2062.
  19. Silber MH, Buchfuhrer MJ, Earley CJ, et al. The management of restless legs syndrome: an updated algorithm. Mayo Clin Proc. 2021;96(7):1921-1937.
  20. Thorpy MJ, Hiller G. The medical and economic burden of narcolepsy: implications for managed care. Am Health Drug Benefits. 2017;10(5):233-241.
  21. Trenkwalder C, Winkelmann J, Oertel W, et al. Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: a randomized trial. Mov Disord. 2017;32(10):1478-1482.
  22. Wang J, O’Reilly B, Venkataraman R, et al. Efficacy of oral iron in patients with restless legs syndrome and a low-normal ferritin: A randomized, double-blind, placebo-controlled study. Sleep Med. 2009;10(9):973-975.
  23. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med. 2005;6(6):432-442.
  24. Winkelman JW. High national rates of high-dose dopamine agonist prescribing for restless legs syndrome. Sleep. 2022; 45(2):zsab212. doi: 10.1093/sleep/zsab212.
  25. Winkelman JW. Treating severe refractory and augmented restless legs syndrome. Chest. 2022;162(3):693-700.
  26. Winkelman JW, Armstrong MJ, Allen RP, et al. Practice guideline summary: Treatment of restless legs syndrome in adults: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2016. 87(24):2585-2593.
  27. Winkelman JW, Johnston L. Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Med. 2004;5(1):9-14.
  28. Winkelman JW, Mackie S, Mei LA, et al. A method to switch from oral dopamine agonists to rotigotine in patients with restless legs syndrome and mild augmentation. Sleep Med. 2016;24:18-23.
  29. Winkelman JW, Purks J, Wipper B. Baseline and 1-year longitudinal data from the National Restless Legs Syndrome Opioid Registry. Sleep. 2021;44(2);zsaa183.
  30. Winkelman JW, Sethi KD, Kushida CA, et al. Efficacy and safety of pramipexole in restless legs syndrome. Neurology. 2006;67(6):1034-1039.
  31. Winkelman JW, Wipper B, Zackon J. Long-term safety, dose stability, and efficacy of opioids for patients with restless legs syndrome in the National RLS Opioid Registry. Neurology. Published online January 25, 2023. doi:10.1212/WNL.0000000000206855.
  32. Winkelman presentation, 2008.
  33. Yeung Laiwah J, Winkelman JW. How effective are treatment guidelines for augmented RLS? Sleep. 2022;45(7):zsac108. doi: 10.1093/sleep/zsac108.
  34. Zhu W, Chernew ME, Sherry TB, Maestas N. Initial opioid prescriptions among U.S. commercially insured patients, 2012-2017. N Engl J Med. 2019;380(11):1043-1052.